Conferences

International Liver Congress - 2014

The International Liver Congress 2014 (ILC 2014), the 49th annual meeting of the European Association for the Study of the Liver (EASL), took place in London, UK, 9-13th April 2014.
Hepatitis C treatment

WHO recommends global use of newest hepatitis C drugs, urges price reductions

New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection

Hepatitis C treatment

Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

Hepatitis C treatment

Sustained response to treatment reduces fatigue in hepatitis C patients

Hepatitis C treatment

Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4

New & experimental hepatitis C treatment

Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence

Hepatitis C treatment

Sofosbuvir for hepatitis C works well despite multiple negative predictive factors

New & experimental hepatitis C treatment

Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6

New & experimental hepatitis C treatment

BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

Hepatitis C treatment

Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease

Hepatitis B

Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

New & experimental hepatitis C treatment

AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis

New & experimental hepatitis C treatment

AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C

New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients

New & experimental hepatitis C treatment

Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis

Hepatitis C treatment

European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs

New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients

New & experimental hepatitis C treatment

88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy

Hepatitis C treatment

AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections